Investigational drug · Phase 2
brivekimig
Also called: SAR442970
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion, Type 1 Diabetes Mellitus.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
5
5 still active
All registered trials
5
Any phase or sponsor naming "brivekimig"
First trial start
2024
Dec 19, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "brivekimig", any sponsor or status.
Conditions studied
As listed on its trial records.
- Focal Segmental Glomerulosclerosis
- Glomerulonephritis Minimal Lesion
- Type 1 Diabetes Mellitus
- Crohn's Disease
- Ulcerative Colitis
- Hidradenitis Suppurativa
Approved drugs for the same conditions: Type 1 diabetes · Crohn's disease · Ulcerative colitis · Hidradenitis suppurativa · Cardiovascular and metabolic · Immunology and inflammation · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "brivekimig" as an intervention, largest first.
- Brivekimig for the Treatment of Moderate to Severe Hidradenitis SuppurativaPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07170917 · 208 participants (planned) · Start Nov 6, 2025 · Primary completion Feb 9, 2027
Drug: Brivekimig; Placebo · For: Hidradenitis Suppurativa
Sites: Phoenix, Arizona; Scottsdale, Arizona; Northridge, California · 85 sites in all
- A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative ColitisPivotal-lookingActive, not recruiting
SanofiSanofi (SNY)
NCT06975722 · 105 participants · Start Jul 7, 2025 · Primary completion Dec 17, 2026
Drug: SAR442970; Placebo · For: Ulcerative Colitis
Sites: Fairhope, Alabama; Escondido, California; Lancaster, California · 61 sites in all
- A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's DiseaseRecruiting
SanofiSanofi (SNY)
NCT06958536 · 99 participants (planned) · Start Jun 3, 2025 · Primary completion Dec 17, 2026
Drug: brivekimig; Placebo · For: Crohn's Disease
Sites: Fairhope, Alabama; Tucson, Arizona; Escondido, California · 78 sites in all
- Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® MoleculeActive, not recruiting
SanofiSanofi (SNY)
NCT06812988 · 84 participants (planned) · Start Feb 28, 2025 · Primary completion Apr 29, 2027
Drug: Brivekimig; Placebo · For: Type 1 Diabetes Mellitus
Sites: Atlanta, Georgia; Columbus, Georgia; Farmington Hills, Michigan · 24 sites in all
SanofiSanofi (SNY)
NCT06500702 · 84 participants (planned) · Start Dec 19, 2024 · Primary completion Dec 23, 2026
Drug: frexalimab; brivekimig and 2 more · For: Focal Segmental Glomerulosclerosis; Glomerulonephritis Minimal Lesion
Sites: Birmingham, Alabama; Orange, California; San Francisco, California · 82 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Combined TNF-α and OX40L targeting as a new treatment option for hidradenitis suppurativa.
Leeuw T, imaitu D, Heyninck K, et al. · J Allergy Clin Immunol Glob 2025
Also in development for Focal Segmental Glomerulosclerosis
- FrexalimabSAR441344Phase 39 trials
Sanofi · Multiple Sclerosis, Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion
- BI 764198ApecotrepPhase 33 trials
Boehringer Ingelheim · Focal Segmental Glomerulosclerosis, Proteinuric Kidney Diseases, Kidney Disease, Chronic
- R3R01Phase 22 trials
River 3 Renal Corp. · Diabetic Kidney Disease, Alport Syndrome, Focal Segmental Glomerulosclerosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Sanofi.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.